L · 0ELV.L · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Guerbet S.A. (0ELV.L) intrinsic value and stock valuation
$6.60as of 2026-11-21 · Mkt cap 132.79M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Guerbet S.A. DCF and intrinsic value
InvestorsCraft values 0ELV.L with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from 0ELV.L’s statements →
Guerbet S.A. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $786.4M | $841.1M | $795.7M | $753.3M | $732.1M |
| Operating income | $1.36M | $42.8M | $38.7M | $30.5M | $36.8M |
| Net income | -$-108.33M | $16.1M | $23.9M | -$-41.12M | $32.6M |
| EPSd | -$-8.6M | $1.28M | $1.9M | -$-3.26M | $2.58M |
| Operating cash flow | $61.3M | $60.7M | $27.4M | $25.9M | $110.7M |
| Capital expenditure | -$-29.86M | -$-32.05M | -$-41.55M | -$-50.52M | -$-48.93M |
| Free cash flow | $31.4M | $28.7M | -$-14.12M | -$-24.63M | $61.8M |
| Total assets | $930M | $1.04B | $1.03B | $939.6M | $1B |
| Total debt | $437.8M | $400.9M | $387.1M | $312M | $333.5M |
| Net debt | $322.3M | $350.7M | $335.8M | $270.4M | $217.8M |
| Total equity | $260.1M | $391.6M | $378.3M | $379.6M | $405.1M |
| Cash and short-term investments | $115.5M | $50.2M | $51.3M | $41.7M | $115.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $786.4M | $841.1M | $795.7M | $753.3M | $732.1M |
| Cost of revenue | $602.4M | $620.1M | $206.2M | $564.2M | $556.4M |
| Gross profit | $184M | $221M | $589.5M | $189.1M | $175.7M |
| Research and development expenses | $0.00 | $76.2M | $81.2M | $70M | $65M |
| Selling, general and administrative expenses | $0.00 | $84.1M | $471M | $80.3M | $53.8M |
| Other expenses | $182.7M | $17.9M | -$-1.38M | $8.36M | $20.1M |
| Operating expenses | $182.7M | $178.2M | $550.8M | $158.7M | $138.9M |
| Cost and expenses | $785.1M | -$-798.27M | $757M | $722.8M | $695.3M |
| Interest income | $370K | $280K | $120K | $30K | $60K |
| Interest expense | $19.8M | $20.5M | $10.6M | $4.57M | $5.34M |
| Depreciation and amortization | $60.9M | $61.3M | $50.9M | $60.8M | $56M |
| Ebitda | $62.2M | $96.7M | $90.1M | $32.3M | $85.1M |
| Operating income | $1.36M | $42.8M | $38.7M | $30.5M | $36.8M |
| Total other income/expenses, net | -$-115.03M | $0.00 | -$-7.86M | -$-63.53M | -$-12.98M |
| Income before tax | -$-113.67M | $14.9M | $30.8M | -$-33.08M | $23.8M |
| Income tax expense | -$-1.01M | $1.43M | $8.64M | $8.03M | -$-8.83M |
| Net income | -$-108.33M | $16.1M | $23.9M | -$-41.12M | $32.6M |
| Weighted average shares outstanding | $12.6M | $12.6M | $12.6M | $12.6M | $12.6M |
| Weighted average diluted shares outstanding | $12.6M | $12.6M | $12.6M | $12.6M | $12.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $115.5M | $50.2M | $51.3M | $41.7M | $115.7M |
| Net receivables | $173.7M | $209.1M | $149.6M | $162.4M | $161.7M |
| Inventory | $296.4M | $305.7M | $305.2M | $276.4M | $203.8M |
| Total current assets | $600.7M | $590M | $581.6M | $509.7M | $495.5M |
| Property, plant and equipment, net | $214.7M | $291.3M | $293.9M | $286.1M | $274.1M |
| Goodwill and intangible assets | $61.5M | $106.7M | $97.1M | $97.9M | $188.6M |
| Long-term investments | $18.8M | $13.3M | $12.9M | $20.2M | $12.8M |
| Total non-current assets | $329.4M | $447.3M | $443.6M | $430M | $505.4M |
| Total assets | $930M | $1.04B | $1.03B | $939.6M | $1B |
| Accounts payable | $85.3M | $95.1M | $92.9M | $103.7M | $81M |
| Short-term debt | $45.7M | $50.3M | $13M | $33.6M | $33.9M |
| Deferred revenue | $0.00 | $0.00 | $29.6M | $19.4M | $15M |
| Total current liabilities | $241.2M | $254.5M | $229.2M | $239.6M | $236.9M |
| Long-term debt | $392.1M | $350.6M | $374.1M | $278.4M | $299.7M |
| Deferred revenue, non-current | $0.00 | $0.00 | $13.5M | $13.4M | $11.2M |
| Total non-current liabilities | $428.7M | $391.2M | $417.7M | $320.5M | $358.9M |
| Capital lease obligations | $10.5M | $21.4M | $22.5M | $21.7M | $19M |
| Total liabilities | $669.9M | $645.7M | $647M | $560.1M | $595.7M |
| Common stock | $12.6M | $12.6M | $12.6M | $12.6M | $12.6M |
| Retained earnings | -$-44.05M | $52.5M | $23.9M | $66.7M | $132.8M |
| Accumulated other comprehensive income (loss) | $286.6M | $317.4M | $341.8M | $288.5M | $247.9M |
| Total equity | $260.1M | $391.6M | $378.3M | $379.6M | $405.1M |
| Total investments | $18.8M | $13.3M | $12.9M | $20.2M | $12.8M |
| Total debt | $437.8M | $400.9M | $387.1M | $312M | $333.5M |
| Net debt | $322.3M | $350.7M | $335.8M | $270.4M | $217.8M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-108.33M | $16.1M | $23.9M | -$-41.12M | $32.6M |
| Depreciation and amortization | $60.9M | $61.3M | $61.2M | $60.8M | $56M |
| Stock-based compensation | $0.00 | $0.00 | $200K | -$-400K | $610K |
| Change in working capital | $5.18M | -$-12.25M | -$-64.45M | -$-58.38M | $13.1M |
| Accounts receivable | $27.3M | -$-27.35M | -$-28.97M | -$-1.56M | -$-6.64M |
| Inventory | -$-18.58M | -$-6.57M | -$-36.27M | -$-68.23M | $4.58M |
| Accounts payable | -$-7.04M | $1.89M | -$-10.34M | $22.2M | $16M |
| Net cash provided by operating activities | $61.3M | $60.7M | $16.8M | $25.9M | $110.7M |
| Investments in property, plant and equipment | -$-36.61M | -$-56.99M | -$-41.55M | -$-50.52M | -$-48.93M |
| Acquisitions, net | $560K | $1.24M | -$-1.95M | $1.19M | $840K |
| Net cash used for investing activities | -$-33.76M | -$-53.16M | -$-59.93M | -$-55.4M | -$-52.24M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $590K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | -$-6.3M | -$-6.31M | -$-10.73M | -$-8.81M |
| Net cash used for financing activities | $40.1M | -$-7.07M | $55.4M | -$-43.99M | -$-36.03M |
| Net change in cash | $65.3M | -$-1.04M | $9.6M | -$-74.05M | $19M |
| Cash at end of period | $115.5M | $50.2M | $51M | $41.7M | $115.7M |
| Operating cash flow | $61.3M | $60.7M | $27.4M | $25.9M | $110.7M |
| Capital expenditure | -$-29.86M | -$-32.05M | -$-41.55M | -$-50.52M | -$-48.93M |
| Free cash flow | $31.4M | $28.7M | -$-14.12M | -$-24.63M | $61.8M |
Line items
Line items
Line items
About Guerbet S.A.
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. The company was founded in 1926 and is headquartered in Villepinte, France.
- CEO
- Philippe Bourrinet
- Employees
- 2.78K
- Beta
- 0.99
Explore
Frequently asked questions
What is the intrinsic value of Guerbet S.A. (0ELV.L)?
InvestorsCraft does not currently publish an intrinsic value for 0ELV.L. How the IC value is calculated.
Is 0ELV.L undervalued?
InvestorsCraft does not publish an undervaluation signal for 0ELV.L at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.